Recombinant human angiostatin (CASI Pharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human angiostatin (CASI Pharmaceuticals)
Drug Alias Namerecombinant human Angiostatin protein重组人血管内皮抑制素
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionAngiogenesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCasi Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCasi Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A